<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00874419</url>
  </required_header>
  <id_info>
    <org_study_id>ML20981</org_study_id>
    <nct_id>NCT00874419</nct_id>
  </id_info>
  <brief_title>Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation</brief_title>
  <acronym>ML20981</acronym>
  <official_title>A Randomized, Open-label, Multi-center Phase III Study of Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With EGFR Exon 19 or 21 Mutation (Optimal)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tongji University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) such as erlotinib&#xD;
      have proved effective in second or third line therapy for advanced non-small cell lung&#xD;
      cancer(NSCLC).It is well tolerated without the side effects usually associated with&#xD;
      chemotherapy. The mutations in EGFR exons 19 or 21 have been reported to be associated with&#xD;
      efficacy of EGFR TKIs.Based on the encouraging preliminary results from the Spanish lung&#xD;
      cancer group' prospective study reported that the efficacy of Tarceva as first line treatment&#xD;
      for metastatic NSCLC patients with EGFR mutation would delay disease progression,prolong&#xD;
      overall survival and be well tolerated, medium Progression-free survival(PFS) was around 12&#xD;
      months and OS reach 24 months，our study is designed to compare PFS between the patients with&#xD;
      mutant EGFR treated by gemcitabine/carboplatin and those by erlotinib in the first-line&#xD;
      setting. We assumed 11 months of PFS on Tarceva arm versus 6 months on chemotherapy arm with&#xD;
      a=0.025(alpha-spend for an interim analysis), 80% power and 12 months enrolment period, 12&#xD;
      months FU duration to calculate the sample size. The sample size is 69 pairs. Considering&#xD;
      about 10% drop-out rate, the final sample size is 152 patients.So, chemo-naive staged IIIb/IV&#xD;
      patients with EGFR mutations in exon 19 or 21 will be enrolled into this open-label,&#xD;
      randomized,multicenter phase III study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Outcome Measures:&#xD;
&#xD;
      Progression-free survival(PFS) Secondary Outcome Measures: Overall response rate(ORR),&#xD;
      overall survival(OS), quality of life(QOL),etc.&#xD;
&#xD;
      Estimated Enrollment: 160 Study Start Date: August 2008 Estimated Study Completion Date:&#xD;
      August 2010&#xD;
&#xD;
      The patients will be randomized into the following two arms:&#xD;
&#xD;
      Arm A: erlotinib 150mg once per day up to disease progression or intolerable toxicity.&#xD;
&#xD;
      Arm B: Gemcitabine (1000mg/m2, IV,d1 and d8) plus Carboplatin (AUC=5, IV d1) repeated every 3&#xD;
      weeks up to 4 cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lung cancer symptoms and health-related quality of life (HRQoL)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>explore the biological markers (tumor tissue)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 receive erlotinib 150 mg oral, once a day until progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gemcitabine/carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>erlotinib 150 mg oral, once a day</description>
    <arm_group_label>erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine/carboplatin</intervention_name>
    <description>gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles</description>
    <arm_group_label>gemcitabine/carboplatin</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Stage IIIB (cytological confirmed with malignant pleural effusion or pericardial&#xD;
             effusion) or histopathological or cytological confirmed stage IV NSCLC or relapsed&#xD;
             after complete resection .&#xD;
&#xD;
          2. EGFR exon19 deletions or exon 21 L858R mutation by the DNA direct PCR sequencing using&#xD;
             fresh tumor sample or paraffin embed tumor sample.&#xD;
&#xD;
          3. Measurable lesions as defined by RECIST criteria .&#xD;
&#xD;
          4. Palliative radiotherapy allowed if it was finished 3 weeks after the first drug&#xD;
             administration, but the target lesions should not be included in the radiotherapy&#xD;
             field.&#xD;
&#xD;
          5. Patients with operation are allowed if the operation is 4 weeks before the first drug&#xD;
             administration&#xD;
&#xD;
          6. Men or women of at least 18 years of age.&#xD;
&#xD;
          7. ECOG Performance status of 0 to 2.&#xD;
&#xD;
          8. Estimated life expectancy of at least 12 weeks.&#xD;
&#xD;
          9. Patient compliance and geographic proximity that allow adequate follow-up.&#xD;
&#xD;
         10. Adequate organ function tested 7 days before the first drug administration:&#xD;
&#xD;
             hemoglobin ≥9 g/dL,absolute neutrophil count (ANC) ≥1.5*109/L, platelets ≥100&#xD;
             *109/L,bilirubin ≤1.5ULN, alkaline phosphatase (AP), aspartate transaminase (AST) and&#xD;
             alanine transaminase (ALT) ≤2.5 upper limited number(ULN) (AP, AST, ALT ≤5ULN is&#xD;
             acceptable if liver has tumor involvement).INR≤1.5, APTT in the normal range(&#xD;
             1.2DLN-1.2ULN),creatinine ≤1.5ULN.&#xD;
&#xD;
         11. Informed consent from the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have received systemic anti-cancer therapy, including Cytotoxic drugs, targeted&#xD;
             therapy, experimental treatment, adjuvant or neo-adjuvant therapy(except the disease&#xD;
             relapse 6 months after the final drug)&#xD;
&#xD;
          2. Wild type EGFR.&#xD;
&#xD;
          3. Uncontrolled pericardial or pleural effusions prior to study entry.&#xD;
&#xD;
          4. History of cardiovascular disease: Congestive Heart Failure &gt; grade II in NYHA.&#xD;
             Unstable angina patients (have angina symptoms in rest) or a new occurrence of angina&#xD;
             (began in the last 3 months) or myocardial infarction happens in the last 6 months&#xD;
&#xD;
          5. Brain metastasis (controlled brain metastasis and steroid free need is excluded).&#xD;
&#xD;
          6. HIV infection&#xD;
&#xD;
          7. Active infection, &gt;grade 2 in Common Terminology Criteria for Adverse Events(CTCAE)&#xD;
             version 3.&#xD;
&#xD;
          8. A history of operation or serious traumatic 3 weeks before the first drug&#xD;
             administration&#xD;
&#xD;
          9. Patient with other malignant tumor except NSCLC 5 years previous to study entry.&#xD;
             Excluding cervical carcinoma in situ, cured basal cell carcinoma, bladder epithelial&#xD;
             tumor [including Ta and Tis]&#xD;
&#xD;
         10. Mixed with small cell lung cancer&#xD;
&#xD;
         11. Unable to swallow drugs.&#xD;
&#xD;
         12. Malabsorption&#xD;
&#xD;
         13. Pregnant or child breast feeding women&#xD;
&#xD;
         14. Childbearing patients will not use a reliable method of contraception before the study&#xD;
             entry, during process of the study and within 30 days after discontinuation of the&#xD;
             study. Reliable contraceptive methods will be determined by principal investigator or&#xD;
             a designated officer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caicun Zhou, MD &amp; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Department, Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>April 1, 2009</study_first_submitted>
  <study_first_submitted_qc>April 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2009</study_first_posted>
  <last_update_submitted>September 23, 2014</last_update_submitted>
  <last_update_submitted_qc>September 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji University</investigator_affiliation>
    <investigator_full_name>Caicun Zhou</investigator_full_name>
    <investigator_title>Shanghai Pulmonary Hospital</investigator_title>
  </responsible_party>
  <keyword>EGFR mutation</keyword>
  <keyword>EGFR-TKI</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

